FOR HEALTHCARE PROFESSIONALS

Dysport® (abobotulinumtoxinA) for injection is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adult patients less than 65 years of age.

Actual patient. Results unretouched. Individual results may vary.

Dysport Clinical Study Results

Meaningful efficacy that’s rapid and enduring

More than half of subjects saw improvement in as little as 2-3 days after treatment1-3* and results may last up to 4 months.2-4† In clinical trials, overall treatment success required at least a 2-grade improvement from baseline by both investigator and subject assessments.

MORE THAN HALF
SAW IMPROVEMENT
2-3
DAYS
AFTER TREATMENT1-3*

EFFICACY
MAY LAST UP TO
4
MOS.

*A secondary endpoint based on Kaplan-Meier estimates of cumulative rate of time to onset of response. The median time to onset of response was 3 days in GL-1 (Dysport 55/105 [52%], Placebo 3/53 [6%] and GL-2 (Dysport 36/71 [51%], Placebo 9/71 [13%]), and 2 days in GL-3 (Dysport 110/200 [55%], Placebo 4/100 [4%]).1-3

†GL-1 and GL-3 evaluated subjects for at least 150 days following treatment. Based on investigator assessment, response was maintained for up to 4 months in both GL-1 (Dysport 24/105 [23%], Placebo 2/53 [4%]) and GL-3 (Dysport 58/200 [29%], Placebo 1/100 [1%]).2-4

  • Success was defined as post-treatment glabellar line severity of none or mild for the combined investigator and subject assessments (composite assessment) on Day 30 with at least a 2-grade improvement.4 The following scale was used to assess efficacy at maximum frown: 0 none, 1 mild, 2 moderate, 3 severe.
  • A subject had to improve from a score of 3 (severe) to a score of 1 or 0 (mild or none), or a score of 2 (moderate) to a score of 0 (none) in order to meet the requirements for overall treatment success.

Study design

Three double-blind, randomized, placebo-controlled clinical studies evaluated the efficacy of Dysport® for use in the temporary improvement of the appearance of moderate to severe glabellar lines. These 3 studies enrolled healthy adults (ages 19–75) with glabellar lines of at least moderate severity at maximum frown. Subjects were excluded if they had marked ptosis, deep dermal scarring, or a substantial inability to lessen glabellar lines, even by physically spreading them apart. The subjects in these studies received either Dysport or placebo. The total dose was 50 units delivered in equally divided aliquots to specified injection sites.

Additional endpoints for each of the studies were post-treatment glabellar line severity of none or mild with at least a 1-grade improvement from baseline for separate investigator and subject assessments at Day 30.

  • Studies GL-1 and GL-3 were 6- and 5-month (respectively) single-dose studies comparing Dysport to placebo
  • GL-2 was a study of Dysport vs placebo in subjects who had received up to 4 treatments of Dysport over the course of the study

Improvement demonstrated for up to four months3

GL-1 was a 6-month, single-dose, double-blind, multicenter, randomized, placebo-controlled study (N=158) to assess the safety and efficacy of 50 Units of Dysport vs placebo in subjects with moderate to severe glabellar lines at maximum frown.3 55 percent (58/105 Dysport subjects versus 0/53 treated with placebo) met the primary endpoint.

Investigator and Subject Assessment of 1+ Grade Improvement in Glabellar Line Severity at Maximum Frown (Study GL-3)

Patients want to come back

In a clinical study of 533 subjects,

97%

said they'd like to receive Dysport again.5*†

*Subject’s satisfaction and self-perception reported 3 weeks after treatment (n=531).

Study Design: Multicenter, prospective, non-interventional observational study conducted in France, Germany, Spain and the United Kingdom (n=533). Subjects were eligible if the investigator had decided to prescribe Dysport according to the labeling. Subjects completed questionnaires at 3 weeks and 4 months after treatment.

Most common side effects

As with any abobotulinumtoxinA treatment, the most common side effects are nose and throat irritation, headache, injection site pain, injection site skin reaction, upper respiratory tract infection, eyelid swelling, eyelid drooping, sinus inflammation and nausea. See below for complete Important Safety Information.

Before + After

Actual patients. Results unretouched.


Identifying Authentic Dysport®

The best way to protect your patients from counterfeit Dysport is to verify that you’re ordering authentic Dysport from an authorized distributor. Be sure to check the packaging of your product to make sure it’s authentic.

There are more anti-counterfeiting measures on the packaging that aren’t listed here. Ask your distributor for more information.


Administering & Reconstitution

Dosing for moderate to severe glabellar lines

Watch to learn more about administering and reconstituting Dysport.

Download the Dysport Reconstitution Guide

Dysport may also be reconstituted with 2.5 mL of preservative-free 0.9% Sodium Chloride Injection USP for a solution of 10 Units per 0.08 mL

Looking for information on injecting Dysport?

Visit GAINHCP.com to register and learn more about injection techniques and training.

Find a Specialist Feature

The Find a Specialist feature on DysportUSA.com makes it easy for website visitors to locate and contact you regarding aesthetic treatment. All you have to do to remain listed on the Dysport Find a Specialist feature is place an order for Dysport a minimum of every six months.

injectable rewards

Get Rewarded

Make every order count by joining ASPIRE Galderma Rewards, the program that offers specialists faster ways to earn instant savings, product discounts and quarterly rebates. It's designed to enhance patient loyalty by enabling patients to redeem their own ASPIRE Galderma Rewards points with you. Members also have access to promotional marketing materials to use within their practices. It’s a win-win!

JOIN NOW

Have Questions? Contact Galderma.

If you would like to place an order for Dysport or have any related product questions, please call 1-844-GALDERM (1-844-425-3376) to speak with a sales representative or email customer service at gss@galdermaservices.com.

For any medical inquiries, including reporting adverse medical reactions to a Galderma product, please call 1-866-735-4137 or email customer service at gss@galdermaservices.com.

  1. Data on file. MA-Y-97-52120-085 (GL-2) Clinical Study Report. Fort Worth, TX: Galderma Laboratories, L.P., 2007.
  2. Data on file. MA-Y-97-52120-718 (GL-3) Clinical Study Report. Fort Worth, TX: Galderma Laboratories, L.P., 2007.
  3. Data on file. MA-Y-97-52120-719 (GL-1) Clinical Study Report. Fort Worth, TX: Galderma Laboratories, L.P., 2007.
  4. Dysport for Injection Package Insert. Fort Worth, TX: Galderma Laboratories, L.P., September 2017.
  5. Molina B, Grangier Y, Mole B, et al. Patient satisfaction after the treatment of glabellar lines with Botulinum toxin type A (Speywood Unit): a multi-centre European observational study. J Eur Acad Dermatol Venereol. 2015;29(7):1382-1388. doi:10.1111/djv.12881. Epub 2014 Dec 12

IMPORTANT SAFETY INFORMATION

Indication: Dysport® (abobotulinumtoxinA) for Injection is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adult patients ˂65 years of age.

Distant Spread of Toxin Effect

Postmarketing reports indicate that the effects of Dysport and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including upper limb spasticity in children, and in approved indications, cases of spread of effect have been reported at doses comparable to or lower than the maximum recommended total dose.

Contraindications

Warnings and Precautions

Adverse Reaction

Drug Interactions

Use in Specific Populations

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see Dysport Full Prescribing Information, including Medication Guide.